JP2025515491A5 - - Google Patents
Info
- Publication number
- JP2025515491A5 JP2025515491A5 JP2024563614A JP2024563614A JP2025515491A5 JP 2025515491 A5 JP2025515491 A5 JP 2025515491A5 JP 2024563614 A JP2024563614 A JP 2024563614A JP 2024563614 A JP2024563614 A JP 2024563614A JP 2025515491 A5 JP2025515491 A5 JP 2025515491A5
- Authority
- JP
- Japan
- Prior art keywords
- patient
- pharmaceutical composition
- valsalva
- treatment
- treatment period
- Prior art date
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263335028P | 2022-04-26 | 2022-04-26 | |
| US202263335209P | 2022-04-26 | 2022-04-26 | |
| US63/335,209 | 2022-04-26 | ||
| US63/335,028 | 2022-04-26 | ||
| US202263336254P | 2022-04-28 | 2022-04-28 | |
| US63/336,254 | 2022-04-28 | ||
| PCT/US2023/019710 WO2023211872A1 (en) | 2022-04-26 | 2023-04-25 | Methods of administering myosin inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025515491A JP2025515491A (ja) | 2025-05-15 |
| JP2025515491A5 true JP2025515491A5 (https=) | 2026-05-01 |
Family
ID=86558746
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024563614A Pending JP2025515491A (ja) | 2022-04-26 | 2023-04-25 | ミオシン阻害剤の投与方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US20230338378A1 (https=) |
| EP (1) | EP4514355A1 (https=) |
| JP (1) | JP2025515491A (https=) |
| KR (1) | KR20250016125A (https=) |
| CN (2) | CN120549937A (https=) |
| AU (1) | AU2023260472A1 (https=) |
| CA (1) | CA3249509A1 (https=) |
| CL (1) | CL2024003237A1 (https=) |
| IL (1) | IL316204A (https=) |
| MX (1) | MX2024013068A (https=) |
| TW (1) | TW202400570A (https=) |
| WO (1) | WO2023211872A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112020014428A2 (pt) | 2018-01-19 | 2020-12-01 | Cytokinetics, Inc. | composto, composição farmacêutica, e, métodos para o tratamento de uma doença cardíaca em um indivíduo, para o tratamento de uma doença ou condição que está associada com cavidade ventricular esquerda pequena e obliteração da cavidade, contração hiperdinâmica do ventrículo esquerdo, isquemia do miocárdio ou fibrose cardíaca, para o tratamento de uma doença ou condição selecionada dentre distrofias musculares e doenças de armazenamento do glicogênio e para inibição do sarcômero cardíaco |
| JP7610985B2 (ja) | 2018-06-26 | 2025-01-09 | サイトキネティックス， インコーポレイテッド | 心臓サルコメア阻害剤 |
| EP3814342B1 (en) | 2018-06-26 | 2022-07-27 | Cytokinetics, Inc. | Cardiac sarcomere inhibitors |
| EP4370116B1 (en) | 2021-07-16 | 2025-01-15 | Cytokinetics, Inc. | Aficamten dosage regimens for treating obstructive hypertrophic cardiomyopathy |
| WO2024182469A1 (en) * | 2023-02-28 | 2024-09-06 | MyoKardia, Inc. | Myosin inhibitors for use in the treatment of hypertrophic cardiomyopathy |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9585885B2 (en) * | 2012-12-10 | 2017-03-07 | Kissei Pharmaceutical Co., Ltd. | Substituted pyrido[2,3-g]quinazolines as dopamine D2 receptor agonists |
| SMT202000071T1 (it) | 2013-06-21 | 2020-03-13 | Myokardia Inc | Composti di pirimidinadione contro le condizioni cardiache |
| BR112020014428A2 (pt) | 2018-01-19 | 2020-12-01 | Cytokinetics, Inc. | composto, composição farmacêutica, e, métodos para o tratamento de uma doença cardíaca em um indivíduo, para o tratamento de uma doença ou condição que está associada com cavidade ventricular esquerda pequena e obliteração da cavidade, contração hiperdinâmica do ventrículo esquerdo, isquemia do miocárdio ou fibrose cardíaca, para o tratamento de uma doença ou condição selecionada dentre distrofias musculares e doenças de armazenamento do glicogênio e para inibição do sarcômero cardíaco |
| JP7610985B2 (ja) | 2018-06-26 | 2025-01-09 | サイトキネティックス， インコーポレイテッド | 心臓サルコメア阻害剤 |
| EP3814342B1 (en) | 2018-06-26 | 2022-07-27 | Cytokinetics, Inc. | Cardiac sarcomere inhibitors |
| JP7447089B2 (ja) | 2018-08-31 | 2024-03-11 | サイトキネティックス， インコーポレイテッド | 心筋サルコメア阻害剤 |
| CN114945372A (zh) * | 2019-11-10 | 2022-08-26 | 迈奥卡迪亚公司 | 用肌球蛋白调节剂的治疗方法 |
| CA3190060A1 (en) * | 2020-08-28 | 2022-03-03 | MyoKardia, Inc. | Methods of treatment with myosin modulator |
-
2023
- 2023-04-25 US US18/306,396 patent/US20230338378A1/en not_active Abandoned
- 2023-04-25 US US18/860,217 patent/US20250288586A1/en active Pending
- 2023-04-25 CA CA3249509A patent/CA3249509A1/en active Pending
- 2023-04-25 KR KR1020247038729A patent/KR20250016125A/ko active Pending
- 2023-04-25 WO PCT/US2023/019710 patent/WO2023211872A1/en not_active Ceased
- 2023-04-25 EP EP23726217.5A patent/EP4514355A1/en active Pending
- 2023-04-25 JP JP2024563614A patent/JP2025515491A/ja active Pending
- 2023-04-25 AU AU2023260472A patent/AU2023260472A1/en active Pending
- 2023-04-25 IL IL316204A patent/IL316204A/en unknown
- 2023-04-25 CN CN202510520246.XA patent/CN120549937A/zh active Pending
- 2023-04-25 CN CN202380047093.0A patent/CN119789856A/zh active Pending
- 2023-04-26 TW TW112115589A patent/TW202400570A/zh unknown
- 2023-12-20 US US18/390,537 patent/US20240115568A1/en active Pending
-
2024
- 2024-10-23 MX MX2024013068A patent/MX2024013068A/es unknown
- 2024-10-23 CL CL2024003237A patent/CL2024003237A1/es unknown
-
2025
- 2025-07-31 US US19/287,195 patent/US20250360132A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025515491A5 (https=) | ||
| JP6309454B2 (ja) | 癌の併用処置 | |
| Martin et al. | Comparison of adenosine, dipyridamole, and dobutamine in stress echocardiography | |
| JP2020529996A5 (https=) | ||
| JP2015526458A5 (https=) | ||
| TW201002676A (en) | Use of dronedarone for the preparation of a medicament for use in the prevention of permanent atrial fibrillation | |
| JPWO2021092598A5 (https=) | ||
| JP2013528649A (ja) | 肺高血圧症の処置のために使用するためのラノラジン | |
| TW202224685A (zh) | 使用烏地那非(udenafil)組合物於改善房坦(fontan)病患心肌功能之方法 | |
| US20080153827A1 (en) | Method for the Treatment or Prevention of Cardiac Hypertrophy | |
| Toyoshima et al. | A case of long-term sildenafil therapy in a young dog with pulmonary hypertension | |
| WO2024255256A1 (zh) | 丙酮酸脱氢酶激酶抑制剂在治疗射血分数保留型心力衰竭中的应用 | |
| Soma et al. | Regular treatment strategy with a large amount of carvedilol for heart failure improves biventricular systolic failure in a patient with repaired tetralogy of Fallot | |
| Eisalo et al. | HAEMODYNAMIC EFFECTS OF TRASICOR®, A NEW BETA‐ADRENERGIC BLOCKING AGENT, IN HYPERTENSIVE PATIENTS | |
| O’Callaghan et al. | Pulmonary hypertension and left heart disease: emerging concepts and treatment strategies | |
| CN119156218A (zh) | 用于治疗心源性休克前期和心源性休克的含有istaroxime的静脉内制剂 | |
| US20220387408A1 (en) | Use of mast cell stabilizer for the treatment of heart failure with preserved ejection fraction | |
| Mathew et al. | Atrioventricular sequential pacing in cardiac amyloidosis: an acute Doppler echocardiographic and catheterization hemodynamic study | |
| Saji et al. | Efficacy of acute inhalation of nitric oxide in patients with primary pulmonary hypertension using chronic use of continuous epoprostenol infusion | |
| Bisognano et al. | Improved cardiac structure and function in early-stage heart failure with chronic treatment using an implantable device: results from European and United States trials of the Rheos® system | |
| JP7439297B2 (ja) | 肥大型心筋症治療用薬学組成物およびその組成物を用いた治療方法 | |
| JP2008530186A (ja) | 心不全治療法 | |
| Bett et al. | EVALUATION OF A NEW BETA‐ADRENERGIC BLOCKING DRUG | |
| Brown et al. | Effect of early treatment with propranolol on left ventricular function four weeks after myocardial infarction. | |
| CN116966176A (zh) | 脂肪酸结合蛋白4抑制剂在治疗射血分数保留型心力衰竭中的应用 |